Sprint just announced the world's first connected payment card at CES. Sprint's Ivo Rook joins Cheddar to tells us about the future of payments, and the company's recent advancements in the space. Rook is the first to hold the newly-created position and reveals his priorities for 2018 and beyond. Sprint and Dynamics unveiled Wallet Card at the Las Vegas electronics expo. He explains what's possible, thanks to the new tech that connected payment option. The card can switch from a credit card to a debit card and back again in addition to storing personal information. Finally, Rook breaks down his predictions for the future of IOT. He also showcases Sprint's advancements in the space and what it has that other competitors do not. He details how the company plans on leveraging its relationship with SoftBank to expand its IOT initiatives.

Share:
More In Business
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More